Compare PayPal Holdings, Inc. (PYPL) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PayPal Holdings, Inc. vs Sanofi SA — how do they compare? PayPal Holdings, Inc. trades at $54.99 (market cap $47.01B), while Sanofi SA trades at $40.22 (market cap $96.81B). The key difference: Sanofi SA is far larger — about 2.1× PayPal Holdings, Inc.'s market cap, and Sanofi SA pays the higher dividend (6.02%). Which is the better fit depends on your goals — on Pluang, investors hold PayPal Holdings, Inc. for 106 Days and Sanofi SA for 94 Days on average.
| PYPL | SNY | |
|---|---|---|
Market Cap | $47.01B | $96.81B |
Volume | 10,493,459 | 2,081,815 |
Sector | Financials | Health |
52-Week High | $75.75 | $52.34 |
52-Week Low | $39.08 | $39.51 |
Typical Hold Time | 106 Days | 94 Days |
Enterprise Value | $49.15B | $116.20B |
Dividend Yield | 1.02% | 6.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PayPal (PYPL) trades at $55.02, up 0.75% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with a P/E of 10.39 and net income margin of 14.36%, while recent earnings beat expectations in two of the last three quarters. Positive sentiment is fueled by a new partnership with Meta and ongoing cost-saving initiatives under CEO Enrique Lores.
The outlook is cautiously optimistic, with a consensus price target of $56.47 offering modest upside. Key opportunities include Venmo growth and AI integration, but risks involve competitive pressures in digital payments and slowing branded checkout growth. Wall Street sentiment is mixed, with 35.71% of analysts rating it a buy.
Sanofi (SNY) trades at $40.23, up 1.69% with recent earnings beats and strong revenue growth to $46.72B in 2025. The stock shows bearish technical signals but maintains solid fundamentals with a 22.2 P/E ratio and 72.77% gross margin. Recent expansion of the Regeneron immunology alliance represents significant strategic positioning for future growth beyond Dupixent.
While near-term technical pressure exists, SNY's fundamental strength and pipeline development provide long-term upside potential. Key risks include patent expiration concerns and competitive pressures in the pharmaceutical sector. Analyst consensus leans slightly positive with 44% buy ratings, though institutional sentiment remains cautious given technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
